ArticleFuture science OA2026
Global, regional, and national burden of early-onset and late-onset colorectal cancer, 1990-2021: a comparative analysis for the Global Burden of Disease Study 2021.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsEarly-onset colorectal cancer (EOCRC) shows a rising global incidence with distinct epidemiological features from late-onset colorectal cancer (LOCRC). This study aimed to compare the epidemiological patterns and temporal trends of EOCRC and LOCRC from 1990 to 2021 based on the Global Burden of Disease (GBD) 2021 dataset.
methodsWe analyzed the incidence, prevalence, mortality, and DALYs of EOCRC and LOCRC across 204 countries using the GBD 2021 dataset. Age-standardized rates (ASRs), estimated annual percentage changes (EAPCs), and socio-demographic index (SDI) stratifications were applied. Projections to 2040 were performed using Bayesian modeling.
resultsIn 2021, LOCRC remained dominant (1.98 million vs. 212,000 cases), but EOCRC exhibited a faster incidence increase (EAPC: 0.37 vs. 0.13). Males were predominant, particularly in cases of EOCRC. Higher SDI was generally associated with higher incidence, though LOCRC declined in regions with SDI >0.85. The rise in EOCRC burden was primarily driven by aging, while population growth drove LOCRC. Projections indicate that ASRs of EOCRC will peak then decrease, whereas LOCRC will continue to rise.
conclusionsLOCRC remains dominant globally, but the rapid increase in EOCRC requires urgent public health action. Age-specific strategies are needed: optimized screening for the elderly to control LOCRC and strengthened risk factor management in young populations to reduce EOCRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.